Galmed Pharmaceutica (GLMD) Stock Price, Quote & News

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 693 8448

Fax: 972 3 693 8447

Website: galmedpharma.com

Address:

16 Abba Hillel Road, Ramat Gan, Israel

Lowlyme Dec. 8 at 4:18 AM

$GLMD AW....LOL

0 · Reply

Lowlyme Dec. 8 at 3:12 AM

$GLMD Allen......

0 · Reply

JamoTries2Trade Dec. 7 at 1:53 AM

$GLMD $NCNA $IXHL $CCCX He’s hilarious 😂

1 · Reply

SpartanVI Dec. 5 at 9:46 PM

$TGL $PBM $CMCT $UPC $GLMD UPC could g

0 · Reply

VolcanicTrades Dec. 5 at 9:31 PM

$TGL share the low float love $PBM $CMCT $UPC $GLMD

0 · Reply

BankOnTheFuture Dec. 5 at 9:23 PM

$GLMD Digesting recent gains nicely. A nice steady upward trend is what we want. Then a buyout by a big pharma 😀

0 · Reply

VolcanicTrades Dec. 5 at 7:56 PM

$GLMD Allen you are going to have PR something good. These nerds and market are keeping you down. One of the most undervalued Bio plays right now with a great drug candidate for a partnership / buyout Your data was good on both PRs. Timing? Could not have been worse as we all thought you bought crypto, and then Bitcoin dropped from 120k+ to 80s. The reiteration of the cash on hand was well timed to bring us out of the mud. (Didn’t buy crypto yet imo) We need something more for some price discovery

0 · Reply

VolcanicTrades Dec. 5 at 1:58 PM

$SMX wow congrats guys. Watching $APLD $GLMD

0 · Reply

getsometoday Dec. 5 at 11:50 AM

$GLMD let’s have another PR today!

0 · Reply

wallstjam Dec. 5 at 1:42 AM

$GLMD I like the float, I like the cash on hand and the quarterly cash burn, i like the product and patent news. I'd like to see more insider owership, but otherwise what am i missing so far it seems very undervalued. Someone with a few million could manipulate the heck outta this i feel. Idk im missing somthing, I'll find it, any insight would be appreciated.

1 · Reply

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 1, 2025, 8:30 AM EST - 6 days ago

Galmed Issues CEO Letter to Shareholders

Nov 26, 2025, 8:30 AM EST - 11 days ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 18, 2025, 8:30 AM EST - 19 days ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 17, 2025, 8:30 AM EST - 20 days ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 25, 2025, 7:30 AM EDT - 3 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

May 27, 2025, 8:00 AM EDT - 6 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 22, 2025, 8:00 AM EDT - 7 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 7 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 17, 2025, 8:30 AM EDT - 8 months ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 15, 2025, 8:30 AM EDT - 8 months ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 8 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 2, 2025, 4:10 PM EDT - 8 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 20, 2025, 8:55 AM EDT - 9 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Mar 15, 2024, 9:00 AM EDT - 1 year ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 22, 2023, 4:05 PM EDT - 2 years ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Mar 29, 2023, 5:00 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

May 17, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 7:30 AM EDT - 3 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 2, 2022, 1:56 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 7:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Apr 28, 2022, 7:00 AM EDT - 3 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Nov 8, 2021, 3:24 PM EST - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 9, 2021, 11:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

Lowlyme Dec. 8 at 4:18 AM

$GLMD AW....LOL

0 · Reply

Lowlyme Dec. 8 at 3:12 AM

$GLMD Allen......

0 · Reply

JamoTries2Trade Dec. 7 at 1:53 AM

$GLMD $NCNA $IXHL $CCCX He’s hilarious 😂

1 · Reply

SpartanVI Dec. 5 at 9:46 PM

$TGL $PBM $CMCT $UPC $GLMD UPC could g

0 · Reply

VolcanicTrades Dec. 5 at 9:31 PM

$TGL share the low float love $PBM $CMCT $UPC $GLMD

0 · Reply

BankOnTheFuture Dec. 5 at 9:23 PM

$GLMD Digesting recent gains nicely. A nice steady upward trend is what we want. Then a buyout by a big pharma 😀

0 · Reply

VolcanicTrades Dec. 5 at 7:56 PM

0 · Reply

VolcanicTrades Dec. 5 at 1:58 PM

$SMX wow congrats guys. Watching $APLD $GLMD

0 · Reply

getsometoday Dec. 5 at 11:50 AM

$GLMD let’s have another PR today!

0 · Reply

wallstjam Dec. 5 at 1:42 AM

1 · Reply

getsometoday Dec. 4 at 8:54 PM

$GLMD frankly with all the possible applications of Aramchol it would only be one of the largest and more diversified bios that could unlock the value here

0 · Reply

VolcanicTrades Dec. 4 at 8:26 PM

$GLMD partnership or buyout regarding aramchol mash is my hunch/ hope. Come on Allen!

1 · Reply

getsometoday Dec. 4 at 8:18 PM

$GLMD I’m loving the pace of updates since the letter to shareholders. Makes me think there are more teed up

1 · Reply

Mr__Man Dec. 4 at 6:17 PM

$GLMD The news for this beauty keeps getting better!! Time to raise your price targets everyone 🚀

0 · Reply

Newbie_Trader50 Dec. 4 at 6:15 PM

$GLMD We need volume to get this 🚀🚀

0 · Reply

ZacksResearch Dec. 4 at 5:59 PM

$GLMD just locked in MAJOR global patent protection — this could be a game-changer for its MASH strategy. 🔥 Galmed secured a new South Korea patent for its Aramchol + Rezdiffra combo, extending worldwide protection to July 2042. With Aramchol showing robust fibrosis improvement and excellent safety, the company sees combination MASH studies as “necessary and imminent.” See the complete stock outlook here👉 https://www.zacks.com/stock/quote/GLMD?q=glmd&cid=sm-stocktwits-0-quote_overview-oc-23552&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_23552

0 · Reply

madan_shatri Dec. 4 at 5:42 PM

$GLMD Next big wall / resistance is at $1.25 , 68k shares on sale. May be they will remove once it rea hes there

0 · Reply

getsometoday Dec. 4 at 5:30 PM

$GLMD get that IP! Adds value to the firm!

0 · Reply

getsometoday Dec. 4 at 5:20 PM

$GLMD obscenely undervalued.

1 · Reply

getsometoday Dec. 4 at 4:54 PM

$GLMD

0 · Reply

JohnTrack Dec. 4 at 3:47 PM

$GLMD just lurking on this one...

0 · Reply

BankOnTheFuture Dec. 4 at 3:24 PM

$GLMD Not even an hour in and we're at 142,600 shares. Attracting attention, let's keep going.

0 · Reply

Market Cap	1.85M
Revenue (ttm)	0.00
Net Income (ttm)	-7.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	237,800
Avg Vol	2,563,854
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	89%
Beta	0.31
Analysts	Hold
Price Target	$12.00